Literature DB >> 11023084

Comparative studies on the efficacy of three anthelminthics on treatment of human strongyloidiasis in Okinawa, Japan.

H Toma1, Y Sato, Y Shiroma, J Kobayashi, I Shimabukuro, M Takara.   

Abstract

A study was undertaken to compare the efficacy of three drugs in the treatment of uncomplicated strongyloidiasis in Okinawa, Japan. Two hundred and eleven patients with confirmed Strongyloides stercoralis infection were given either ivermectin, 6 mg in a single dose, albendazole, 400 mg/day for 3 days or pyrvinium pamoate, 5 mg/kg/day for 3 days. For each treatment, the same regimen was repeated once 2 weeks later. Efficacy was evaluated at 2 weeks, 6 months and 12 months after the second course of treatment. Each follow-up examination included a parasitological examination of z stool specimens, using the agar-plate culture method. Coprological cure was obtained in 65 of the 67 patients treated with ivermectin (97.0%), in 65 of the 84 patients treated with albendazole (77.4%) and only in 14 of the 60 patients who were given pyrvinium pamoate (23.3%). The cure rates were lower in males and in the patients with concurrent HTLV-1 infection. An epidemiological feature of Strongyloides infection in recent Okinawa might allow workers to evaluate the exact efficacy of the treatment for an extended period, over a year, without the possibility of reinfection from the environment.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11023084

Source DB:  PubMed          Journal:  Southeast Asian J Trop Med Public Health        ISSN: 0125-1562            Impact factor:   0.267


  14 in total

Review 1.  [Therapy of tropical diseases after returning from travel].

Authors:  G D Burchard; H Sudeck
Journal:  Internist (Berl)       Date:  2003-05       Impact factor: 0.743

2.  Evidence-based clinical guidelines for immigrants and refugees.

Authors:  Kevin Pottie; Christina Greenaway; John Feightner; Vivian Welch; Helena Swinkels; Meb Rashid; Lavanya Narasiah; Laurence J Kirmayer; Erin Ueffing; Noni E MacDonald; Ghayda Hassan; Mary McNally; Kamran Khan; Ralf Buhrmann; Sheila Dunn; Arunmozhi Dominic; Anne E McCarthy; Anita J Gagnon; Cécile Rousseau; Peter Tugwell
Journal:  CMAJ       Date:  2010-06-07       Impact factor: 8.262

3.  Pulmonary Strongyloidiasis: The Varied Clinical Presentations.

Authors:  Babak Mokhlesi; Oksana Shulzhenko; Prasad S Garimella; Leslie Kuma; Catherine Monti
Journal:  Clin Pulm Med       Date:  2004-01

Review 4.  Evidence-Based Guidelines for Screening and Management of Strongyloidiasis in Non-Endemic Countries.

Authors:  Ana Requena-Méndez; Dora Buonfrate; Joan Gomez-Junyent; Lorenzo Zammarchi; Zeno Bisoffi; José Muñoz
Journal:  Am J Trop Med Hyg       Date:  2017-07-27       Impact factor: 2.345

5.  Strongyloides stercoralis infection in the immunocompromised host.

Authors:  Roshan Ramanathan; Thomas Nutman
Journal:  Curr Infect Dis Rep       Date:  2008-05       Impact factor: 3.725

6.  Maltreatment of Strongyloides infection: case series and worldwide physicians-in-training survey.

Authors:  David R Boulware; William M Stauffer; Brett R Hendel-Paterson; Jaime Luís Lopes Rocha; Raymond Chee-Seong Seet; Andrea P Summer; Linda S Nield; Khuanchai Supparatpinyo; Romanee Chaiwarith; Patricia F Walker
Journal:  Am J Med       Date:  2007-06       Impact factor: 4.965

7.  Efficacy and safety of single and double doses of ivermectin versus 7-day high dose albendazole for chronic strongyloidiasis.

Authors:  Yupin Suputtamongkol; Nalinee Premasathian; Kid Bhumimuang; Duangdao Waywa; Surasak Nilganuwong; Ekkapun Karuphong; Thanomsak Anekthananon; Darawan Wanachiwanawin; Saowaluk Silpasakorn
Journal:  PLoS Negl Trop Dis       Date:  2011-05-10

8.  Randomized clinical trial on ivermectin versus thiabendazole for the treatment of strongyloidiasis.

Authors:  Zeno Bisoffi; Dora Buonfrate; Andrea Angheben; Marina Boscolo; Mariella Anselmi; Stefania Marocco; Geraldo Monteiro; Maria Gobbo; Giulia Bisoffi; Federico Gobbi
Journal:  PLoS Negl Trop Dis       Date:  2011-07-26

Review 9.  Advocating for both Environmental and Clinical Approaches to Control Human Strongyloidiasis.

Authors:  Meruyert Beknazarova; Harriet Whiley; Kirstin Ross
Journal:  Pathogens       Date:  2016-09-30

Review 10.  Strongyloidiasis: A Disease of Socioeconomic Disadvantage.

Authors:  Meruyert Beknazarova; Harriet Whiley; Kirstin Ross
Journal:  Int J Environ Res Public Health       Date:  2016-05-20       Impact factor: 3.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.